A band of clinicians and chronic pain advocates are pushing regulators to scrutinize a controversial risk rating tool.

Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss the impact of President Trump's tariff policy and ...

Vertex misses quarterly results on weaker-than-expected sales for cystic fibrosis drug Vertex Pharmaceuticals ... and former U.S. Food and Drug Administration Commissioner Scott Gottlieb would ...

Scott Furness, to serve as its new senior vice resident of regulatory and scientific affairs. Furness comes to CHPA from the Food and Drug Administration where he spent more than 25 years in ...

Jennifer Maloney is deputy corporate bureau chief and retail editor for The Wall Street Journal in New York. She helps oversee a team of reporters covering consumer brands, retail, manufacturing, ...

Jim O’Neill, President Donald Trump’s nominee for the second-highest position at the Department of Health and Human Services, ...

Kennedy Jr. has railed against what he sees as a “revolving door” between workers at drug companies and the Food and Drug Administration ... former FDA commissioner Scott Gottlieb estimated ...

New FDA commissioner Scott Gottlieb has said reducing costs of drugs will be an important ... who had boasted that his administration would sweep away many FDA regulations. Gottlieb added that ...

Even though it looks highly likely that president Donald Trump’s nomination for FDA commissioner, Scott Gottlieb ... George W Bush administration, the main drawback with Gottlieb is a ...